These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Immunotherapy in melanoma: Recent advances and future directions. Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635 [TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
9. Overview of tumor immunotherapy based on approved drugs. Chen Z; Hu T; Zhou J; Gu X; Chen S; Qi Q; Wang L Life Sci; 2024 Mar; 340():122419. PubMed ID: 38242494 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Toxicities: A New Electronic Documentation Template to Improve Patient Care. Reimschissel E; Dela Cruz B; Gonzalez M; Buitrago J; Goodman C; Johnston PA Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):41-44. PubMed ID: 28315559 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of melanoma: efficacy and mode of action. Wieder T; Brenner E; Braumüller H; Röcken M J Dtsch Dermatol Ges; 2016 Jan; 14(1):28-37. PubMed ID: 26713633 [TBL] [Abstract][Full Text] [Related]
12. Aging population. Ellison D; White D; Farrar FC Nurs Clin North Am; 2015 Mar; 50(1):185-213. PubMed ID: 25680496 [TBL] [Abstract][Full Text] [Related]
13. [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]. Moura B; Homicsko K; Berthod G; Cerottini JP; Guggisberg D; Gaide O; Maillard MH; Michielin O Rev Med Suisse; 2015 May; 11(475):1108, 1110-4. PubMed ID: 26152085 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the management of advanced melanoma: the next steps. Zikich D; Schachter J; Besser MJ Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145 [TBL] [Abstract][Full Text] [Related]
15. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Kakavand H; Wilmott JS; Long GV; Scolyer RA Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392 [TBL] [Abstract][Full Text] [Related]
16. Newer developments in the immunotherapy of malignant melanoma. Maslin B; Alexandrescu DT; Ichim TE; Dasanu CA J Oncol Pharm Pract; 2014 Feb; 20(1):3-10. PubMed ID: 23435643 [TBL] [Abstract][Full Text] [Related]
18. Update on New Therapies With Immune Checkpoint Inhibitors. Peterson JJ; Steele-Moses SK Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513 [TBL] [Abstract][Full Text] [Related]
19. [Breaking immune tolerance in cancer]. Desbois M; Champiat S; Chaput N Bull Cancer; 2015 Jan; 102(1):34-52. PubMed ID: 25609492 [TBL] [Abstract][Full Text] [Related]
20. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors. Andtbacka RH Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099 [No Abstract] [Full Text] [Related] [Next] [New Search]